Sotera Health (NYSE:SHC) Price Target Cut to $8.00

Sotera Health (NYSE:SHCGet Rating) had its price objective reduced by analysts at The Goldman Sachs Group from $9.00 to $8.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price suggests a potential downside of 3.03% from the company’s previous close.

Several other analysts also recently weighed in on SHC. Barclays downgraded Sotera Health from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $7.00 to $6.00 in a research note on Tuesday, November 15th. TheStreet lowered Sotera Health from a “c-” rating to a “d” rating in a research report on Monday, September 19th. JPMorgan Chase & Co. lowered their price objective on Sotera Health from $9.00 to $6.00 and set an “underweight” rating for the company in a research report on Thursday, November 3rd. Citigroup cut Sotera Health from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $25.00 to $9.00 in a research note on Wednesday, October 5th. Finally, Royal Bank of Canada cut their price target on Sotera Health from $25.00 to $8.00 and set an “outperform” rating on the stock in a research note on Thursday, November 3rd. Two research analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Sotera Health presently has an average rating of “Hold” and an average price target of $15.89.

Sotera Health Trading Up 3.4 %

Shares of NYSE:SHC opened at $8.25 on Wednesday. Sotera Health has a 12-month low of $5.78 and a 12-month high of $24.90. The business’s fifty day simple moving average is $7.32 and its 200-day simple moving average is $15.14. The company has a market capitalization of $2.33 billion, a PE ratio of 18.75 and a beta of 1.27. The company has a current ratio of 3.00, a quick ratio of 2.74 and a debt-to-equity ratio of 2.97.

Hedge Funds Weigh In On Sotera Health

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SNC acquired a new position in Sotera Health in the 3rd quarter valued at about $37,000. Fox Run Management L.L.C. acquired a new position in Sotera Health in the 3rd quarter valued at about $75,000. Cipher Capital LP acquired a new position in Sotera Health in the 3rd quarter valued at about $77,000. Ensign Peak Advisors Inc increased its position in Sotera Health by 156.6% in the 3rd quarter. Ensign Peak Advisors Inc now owns 13,290 shares of the company’s stock valued at $91,000 after acquiring an additional 8,110 shares during the period. Finally, MetLife Investment Management LLC acquired a new position in Sotera Health in the 1st quarter valued at about $139,000. Institutional investors and hedge funds own 88.38% of the company’s stock.

Sotera Health Company Profile

(Get Rating)

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.

Recommended Stories

Analyst Recommendations for Sotera Health (NYSE:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.